Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock

May 31, 2021 updated by: Efferon JSC

Early Efferon LPS Hemoperfusion Through Hypercrosslinked Styrene-divinylbenzene Copolymer With Immobilized LPS-selective Ligand for Treatment of Patients With Septic Shock

Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve treatment outcomes in patients with septic shock. Aim of the study: to evaluate safety and feasibility of clinical use of an extracorporeal blood adsorber based on a hypercrosslinked styrene-divinylbenzene copolymer with immobilized lipopolysaccharide (LPS)-selective ligand designed to remove endotoxins from the bloodstream to treat patients with septic shock.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Introduction. Sepsis, according to the latest consensus definition (SEPSIS-3, 2016), is a disease characterized by life-threatening organ failure resulting from a disordered regulation of the body's response to infection. Sepsis continues to be the leading cause of death in intensive care units in almost any country in the world.

The highest mortality rate in sepsis is associated with the development of septic shock (SS). Septic shock is defined as sepsis (according to the criteria of SEPSIS-3, 2016) accompanied by severe hemodynamic, cellular and metabolic disorders, with a higher risk of fatal outcome than sepsis without shock. On average, SS is detected with a frequency of 8.3-10.4% among ICU patients, and its mortality, according to recent estimates, reaches 38-50% and even higher, exceeding 50-80% with such comorbidity as diabetes mellitus.

Success in treating septic shock is traditionally associated with adequate vasopressor, antibacterial, and anti-shock therapy, including inotropic support. At the same time, such factors as multiple antibiotic resistance of Gram-negative bacteria, changes in the intestinal microbiota and associated profile of bacterial metabolites entering circulation and participating in the pathogenesis of sepsis, other bacterial products such as pathogen-associated molecular patterns and cytokines induced by them, bacterial endotoxins contributing most to the multiorgan failure, nowadays are considered as new targets for developing effective mtools of controlling the septic shock sequelae.

Taking into account the key role of bacterial endotoxins in the pathogenesis of septic shock and the absence of a significant trend for reducing mortality in response to the medication treatment, increasing interest is being focused on extracorporeal methods of clearing the endotoxins and inflammatory immune mediators from the bloodstream. Such methods are designed to reduce the levels of pathogenetically significant molecules in the systemic circulation down to less critical values at least for a certain period of time in order to enable the immune system and antibiotics to reduce the bacterial load and the production of new endotoxin molecules.

The methods used and developed with respect to selective adsorption of endotoxin molecules from the bloodstream are promising. They provide, at early stages of the disease, interruption of the pro-inflammatory cascade initiated by inborn immune cells and causing organ dysfunction. At the same time, the place of LPS-selective hemoperfusion in sepsis therapy is still not clearly defined.

Recently, the first clinical experience of using a new generation of Efferon LPS medical device for successful treatment of a patient with sepsis has been reported [Ushakova N.D., Tikhonova S.N., Rozenko D.A. Hemosorption by a Column Adsorber Based on Hyper-Cross-Linked Styrene-Divinylbenzene Copolymer with Immobilized Lipopolysaccharide-Selective Ligand in Combined Intensive Care of Lung Cancer-Related Postoperative Acute Lung Injury (Case Report). Obshchaya Reanimatologiya=General Reanimatology. 2020; 16 (4): 14-20. [In Russ.] DOI: 10.15360/1813-9779-2020-4-14-20].

This extracorporeal adsorber contains a multimodal sorbent based on a hypercrosslinked styrene-divinylbenzene copolymer with a covalently immobilized ligand to the Lipid A domain of LPS molecule. The combination of a porous matrix containing mesopores and ligand provides selective and simultaneous action of the adsorbent on two types of dissimilar therapeutic targets (cytokines and endotoxins, respectively).

Efferon LPS (Efferon JSC, Moscow, Russia) is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.

The aim of the study was to evaluate the safety and clinical eligibility of a novel medical device based on a hypercrosslinked styrene divinylbenzene copolymer with an immobilized LPS-selective ligand designed to remove endotoxins from the bloodstream for treatment of patients with septic shock.

Materials and methods. Nine patients (mean age 58 years, 5 men and 4 women, initial median APACHE II score 28 points, SOFA score 10 points) with confirmed gram-negative bacterial infection and septic shock (SEPSIS-3, 2016) underwent LPS-selective hemoperfusion using Efferon LPS for 6 hours, followed by prolonged venous-venous hemodiafiltration. The decision to use LPS-selective hemoperfusion in a particular patient was made by the attending doctor with the participation of a medical consultant team in accordance with clinical indications.

Before hemoperfusion (day 0), immediately after it, one day after its end (day 1) and once a day for the next 4 days, patients were determined hemodynamic parameters, oxygenation, signs of organ failure, leukocyte count, procalcitonin levels, C- reactive protein, IL 1β, clinical chemistry parameters. All patients underwent a test for endotoxin activity at the same time. Endotoxin Activity Assay Kit (EAA TM) (Spectral Medical Inc., Canada; Certificate No. FSZ 2009/04982) was used to determine endotoxin activity (EAA) using chemiluminescent rapid test and immunodiagnostic reagent set according to the manufacturer's protocol.

SOFA and APACHE II scales were used for comprehensive assessment of clinical status and risk of adverse outcomes. In the course of treatment, adverse reactions during the procedures and final outcome of the hospital stay (duration of stay in ICU and other departments, 28-day mortality) were assessed.

Hemoperfusion through the Efferon LPS adsorber was performed in hospitalized patients with unstable hemodynamic parameters, obvious signs of septic shock according to SEPSIS-3 (2016), during the first hours after making the diagnosis of septic shock. The procedures were performed on MultiFiltrate (Fresenius) along the veno-venous bypass. After LPS-selective hemoperfusion procedure, continuous veno-venous hemodiafiltration (CVVHDF) was performed on MultiFiltrate (Fresenius).

Statistical analysis. Statistical analysis of research data was carried out using descriptive statistics. The test for normal distribution of paired variable changes before and after hemosorption was performed for each data group using the Shapiro-Wilk test, the hypothesis of normal distribution was rejected at P<0.05. To assess the statistical significance of differences between groups, in distribution differing from the normal, the bilateral Wilcoxon test for paired samples or Mann-Witney test for independent groups were used. In normal distribution of paired variable changes in groups, the significance of differences was assessed using the Student's paired bilateral t-criterion. The value of P<0.05 was taken as the cutoff value for statistical significance. When comparing groups by categories of treatment outcome "survived-dead" in the group of patients undergoing hemosorption and the group of patients with abdominal sepsis who did not get hemosorbents (control sample), the exact Fisher's test and the calculation of sample power adequacy at alpha=0.05 were used (SigmaPlot 12.5, Systat Software,USA). The Fisher test was also used to compare the percentage of abdominal sepsis and the sex distribution between the above-mentioned groups of patients.

The ultimate goal of the study was to improve treatment outcomes in patients with septic shock and acute renal failure through combined use of LPS-selective hemoperfusion and prolonged venovenous hemodiafiltration.

Study Type

Observational

Enrollment (Actual)

9

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Russian Federation
      • Moscow, Russian Federation, 119049
        • N.I. Pirogov City Clinical Hospital No. 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study included 9 surgical patients with clinical signs of septic shock (SEPSIS-3, 2016) who were admitted to the intensive care unit (ICU) in 2019-2020.

Description

Inclusion Criteria:

  1. Gram-negative agents in the blood; or detection of an infection focus suggesting Gram-negative agents; or suspected infection based on patient condition, presence of at least two criteria for a systemic inflammatory response and procalcitonin (PCT) level ≥ 2 ng/ml;
  2. severity of organ dysfunction assessed on a Sepsis-related Organ Failure Assessment (SOFA) scale > 4 points as a result of an evident or suspected infection;
  3. need for vasopressor support after administration of fluids to maintain an average blood pressure of at least 65 mmHg. and lactate level in serum > 2 mmol/l (optional, for diagnosis of septic shock).

An additional criterion was the endotoxin activity exceeding 0.6 units according to EAA

Exclusion Criteria:

  • terminal condition,
  • ongoing internal bleeding or high risk of bleeding,
  • severe heart failure (left ventricular ejection fraction < 25%),
  • decompensated liver failure,
  • body weight less than 20 kg,
  • age < 18 or > 80 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of Efferon LPS hemoperfusion on vasopressor dose after initiation of use in patients with abdominal sepsis complicated by septic shock.
Time Frame: 1-120 hours
The time (number of hours) from inclusion in the study to the earliest time that the 'resolution of septic shock' event is achieved. Event criteria is end of vasopressor support (persistence of effect - for 4 hours).
1-120 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of the Efferon LPS hemoperfusion on pulmonary oxygen metabolism function in patients with abdominal sepsis complicated by septic shock
Time Frame: 1-120 hours
Value of oxygenation index (Pa02 / Fi02 (Pa) every 24 hours ± 1 hour from the start of hemoperfusion (hour 0) to 120 hours.
1-120 hours
Effect of LPS Efferon hemoperfusion on SOFA scores in patients with abdominal sepsis complicated by septic shock.
Time Frame: 1-120 hours
Value of indicators on the SOFA scale every 24 hours ± 1 hour from the start of hemoperfusion (hour 0) to 120 hours.
1-120 hours
Effect of LPS Efferon hemoperfusion on procalcitonin levels in patients with abdominal sepsis complicated by septic shock.
Time Frame: 1-120 hours
Value of procalcitonin levels every 24 hours ± 1 hour from the start of hemoperfusion (hour 0) to 120 hours
1-120 hours
Effect of LPS Efferon hemoperfusion on endotoxin activity in patients with abdominal sepsis complicated by septic shock.
Time Frame: 1-72 hours
Value of endotoxin levels every 24 hours ± 1 hour from the start of hemoperfusion (hour 0) to 72 hours
1-72 hours
Effect of LPS Efferon hemoperfusion on IL-1β levels in patients with abdominal sepsis complicated by septic shock.
Time Frame: 1-24 hours
Value of IL-1β levels from the start of hemoperfusion (hour 0) to 24 hours.
1-24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Efferon JSC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 13, 2019

Primary Completion (Actual)

March 20, 2020

Study Completion (Actual)

October 12, 2020

Study Registration Dates

First Submitted

April 26, 2021

First Submitted That Met QC Criteria

May 7, 2021

First Posted (Actual)

May 13, 2021

Study Record Updates

Last Update Posted (Actual)

June 3, 2021

Last Update Submitted That Met QC Criteria

May 31, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • efferon-lps-2020-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Septic Shock

Clinical Trials on Efferon LPS

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe